olivLaw · US equity research
Quanome Technologies, Inc. QNME
Arrangement of Transportation of Freight & Cargo · SIC 4731 · Vertical: Arrangement of Transportation of Freight & Cargo (SIC 4731)
Quanome Technologies, Inc. (formerly Lakeside Holding Limited) currently operates mainly as a pharmaceutical distributor in China through Hupan Pharmaceutical, after disposing of its cross-border freight business. The company is moving into quantum technologies and AI compute infrastructure, activities still at an early stage with no revenue reported, so its profile is in transition. Revenue from continuing operations reached 5.85 mil USD in fiscal 2026.
At the close of 04 Nov 2026, Quanome Technologies, Inc. (QNME) stock was 0.39 USD (−10.14% on the day), with market capitalisation 13.4 m USD, beta 0.98, 52-week range 0.26–1.27 USD. Latest reported quarter (Q4 2026): revenue of 742.3 k USD (−63.7% YoY), net income of -6.7 m USD, diluted EPS -0.19 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 41.7
- weak (30–45)
- Bollinger (20, 2)
- 0.27 – 0.74
- in the lower half of the band · %B 0.26 · band width 94.2%
- SMA 50 / 200
- 0.48 / 0.58
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.04 / -0.03
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −32.6% | −1.1% | −31.5 pp | — |
| 3 months | −23.5% | −0.5% | −23.1 pp | — |
| 6 months | −35.0% | +4.4% | −39.4 pp | — |
| Year to date | −56.2% | +12.3% | −68.5 pp | — |
| 1 year | −65.5% | +13.5% | −79.0 pp | −40.0% |
| 3 years | unavailable | +76.4% | unavailable | −70.0% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q4 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.1 m | 3.6 m | 497.3 k | 2.0 m | 6.1 m | 7.0 m | 1.3 m | 742.3 k |
| Cost of revenue | 3.6 m | 3.6 m | 119.2 k | 971.4 k | 5.0 m | 5.1 m | 348.2 k | 202.2 k |
| Gross profit | 522.5 k | -42.2 k | 378.1 k | 1.1 m | 1.1 m | 1.9 m | 979.5 k | 540.1 k |
| Operating income | -1.3 m | -2.0 m | -329.5 k | -3.2 k | -1.3 m | -1.5 m | -1.6 m | -6.8 m |
| Depreciation & amortisation | — | — | 93.8 k ≈ | — | — | — | — | — |
| Interest expense | 28.1 k | 40.9 k | 40.5 k | 114.5 k | 196.4 k | 183.4 k | 26.7 k | 302 |
| Pre-tax income | -1.2 m | -1.9 m | -358.4 k | -175.5 k | -1.3 m | -1.5 m | -1.5 m | -6.7 m |
| Income tax | 89.6 k | 0 ≈ | 18.6 k | 193.7 k | 36.0 k | 45.0 k | 29.6 k | -18.9 k |
| Net income | -1.3 m | -1.9 m | -1.1 m | -893.1 k | -1.4 m | -1.6 m | 142.4 k | -6.7 m |
| Diluted EPS | -0.18 | -0.26 | -0.14 | -0.12 ≈ | -0.09 | -0.08 | 0.01 | -0.19 ≈ |
| Operating cash flow | -1.4 m | -530.2 k ≈ | -238.3 k ≈ | -483.7 k | -4.0 m | -453.5 k ≈ | — | — |
| Capex | 5.8 k | 30.3 k ≈ | -25.2 k ≈ | 9.5 k | — | — | — | — |
| Share repurchases | 879.6 k | -74.2 k ≈ | -213.2 k ≈ | 213.8 k | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | ⚠ 2025 | 2026 |
|---|---|---|---|---|
| Revenue | 12.9 m | 18.3 m | 2.8 m | 5.9 m |
| Revenue YoY | unavailable | +42.3% | — | +111.8% |
| Net income | 983.6 k | -225.3 k | -5.2 m | -9.5 m |
| Net income YoY | unavailable | −122.9% | — | unavailable |
| Diluted EPS | 0.16 | -0.04 | -0.69 | -0.36 |
| Diluted EPS YoY | unavailable | −125.0% | — | unavailable |
| net % | 7.6% | -1.2% | -189.9% | -162.1% |
| Free cash flow | 21.0 k | unavailable | -2.7 m | unavailable |
The series breaks before 2025: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 30 Jun 2026
- Cash
- 670.3 k USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 7.0 m USD
- Total assets
- 11.7 m USD
- Debt / equity
- unavailable
- Current ratio
- 2.46x
- ROE
- -192.5%
- ROA
- -72.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 12.9 m | 18.3 m | 2.8 m | 5.9 m | SEC (XBRL)· 25 Sept 2026verified |
| Cost of revenue | 10.3 m | 14.6 m | 1.2 m | 2.5 m | SEC (XBRL)· 25 Sept 2026verified |
| Gross profit | 2.6 m | 3.7 m | 1.6 m | 3.3 m | SEC (XBRL)· 25 Sept 2026verified |
| Operating income | 246.9 k | -526.0 k | -1.5 m | -10.2 m | SEC (XBRL)· 25 Sept 2026verified |
| Interest expense | 123.6 k | 108.0 k | 139.0 k | 149.7 k | SEC (XBRL)· 25 Sept 2026verified |
| Pre-tax income | 1.0 m | -295.6 k | -1.7 m | -10.0 m | SEC (XBRL)· 25 Sept 2026verified |
| Income tax | 65.1 k | -67.3 k | 212.3 k | 91.7 k | SEC (XBRL)· 25 Sept 2026verified |
| Net income | 983.6 k | -225.3 k | -5.2 m | -9.5 m | SEC (XBRL)· 25 Sept 2026verified |
| Diluted EPS | 0.16 | -0.04 | -0.69 | -0.36 | SEC (XBRL)· 25 Sept 2026verified |
| Weighted average diluted shares | 6.0 m | 6.0 m | 7.6 m | 25.7 m | SEC (XBRL)· 25 Sept 2026verified |
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 174.0 k | 123.6 k | 4.8 m | 670.3 k | SEC (XBRL)· 25 Sept 2026verified |
| Receivables | — | — | 1.4 m | 1.1 m | SEC (XBRL)· 25 Sept 2026verified |
| Inventories | — | — | 96.5 k | 196.6 k | SEC (XBRL)· 25 Sept 2026verified |
| Current assets | 2.4 m | 3.5 m | 10.3 m | 11.0 m | SEC (XBRL)· 25 Sept 2026verified |
| Property, plant & equipment, net | 489.5 k | 344.9 k | 160.6 k | 191.1 k | SEC (XBRL)· 25 Sept 2026verified |
| Intangibles (excl. goodwill) | — | — | 365.4 k | 280.0 k | SEC (XBRL)· 25 Sept 2026verified |
| Total assets | 5.5 m | 9.2 m | 14.4 m | 11.7 m | SEC (XBRL)· 25 Sept 2026verified |
| Accounts payable | — | — | 1.0 m | 650.6 k | SEC (XBRL)· 25 Sept 2026verified |
| Long-term debt | — | 883.3 k | 1.4 m | — | SEC (XBRL)· 14 Oct 2025verified |
| Current liabilities | 2.8 m | 5.9 m | 9.7 m | 4.5 m | SEC (XBRL)· 25 Sept 2026verified |
| Total liabilities | 4.6 m | 8.6 m | 11.6 m | 4.6 m | SEC (XBRL)· 25 Sept 2026verified |
| Equity | 854.8 k | 639.8 k | 2.8 m | 7.0 m † | SEC (XBRL)· 25 Sept 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | 39.3 k | -53.6 k | -2.7 m | — | SEC (XBRL)· 14 Oct 2025verified |
| Capex | 18.3 k | — | 20.4 k | 2.0 k | SEC (XBRL)· 25 Sept 2026verified |
| Free cash flow | 21.0 k ≈ | — | -2.7 m ≈ | — | SEC (XBRL)· 14 Oct 2025derived |
| Investing cash flow | -18.3 k | -78.8 k | -688.3 k | — | SEC (XBRL)· 14 Oct 2025verified |
| Financing cash flow | -253.1 k | 78.8 k | 8.2 m | — | SEC (XBRL)· 14 Oct 2025verified |
| Share repurchases | 47.5 k | — | 805.9 k | — | SEC (XBRL)· 25 Sept 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 39.6% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 13.4 m USD
Key indicators
Coverage and freshness
Score by group
40% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 39.6% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -162.1% | 13 (vs peers) | 16% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -23.1% | 0 (on a fixed band) | 21% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -68.1x | 0 (on a fixed band) | 16% |
| Current ratio · Balance sheet | 2.5x | 100 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -38.7% | 0 (on a fixed band) | 21% |
| Shareholder yield (distributions) · Returns | 6.0% | 86 (on a fixed band) | 16% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial13/100 · 1/3 factors with a value
- Returns· partial86/100 · 1/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Quanome Technologies, Inc. (QNME). Latest full fiscal year: 2026; data up to 2026-06-30.
Figures computed from the financial statements: revenue 5.9 m USD in 2026; YoY growth 111.8%; net margin -162.1%; ROE -192.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 39.6% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 2.5x
- Shareholder yield (distributions): 6.0%
What contradicts it
- Net margin: -162.1%
- Revenue CAGR 3Y: -23.1%
- Interest coverage: -68.1x
- FCF yield: -38.7%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Arrangement of Transportation of Freight & Cargo (SIC 4731) · same industry (4-digit SIC) · compared with 16 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| EXPDExpeditors International Of Washington, Inc. | 25.5 bn | 25.1 | 45.0% | 7.9% | +4.4% | +35% / +64% |
| CHRWC.h. Robinson Worldwide, Inc. | 15.5 bn | 24.0 | 38.9% | 3.7% | −8.4% | −16% / +63% |
| BCOBrink’s Co | 4.7 bn | 29.6 | 56.0% | 2.9% | +5.0% | +1% / +43% |
| FWRDForward Air Corporation | 644.5 m | — | -1,574.1% | -11.4% | +0.8% | −17% / −70% |
| RLGTRadiant Logistics, Inc. | 450.2 m | 24.6 | 8.0% | 2.0% | +3.5% | +54% / +60% |
| NCEWNew Century Logistics (bvi) Limited | 422.8 m | — | -185.6% | -24.2% | −15.5% | +311% / unavailable |
| PSIGPS International Group Ltd. | 80.1 m | — | -440.7% | -28.6% | −39.0% | +28% / unavailable |
| CRGOFreightos Ltd | 32.8 m | — | -35.8% | -59.5% | +23.9% | −79% / −79% |
| VNTGVantage Corp | 14.3 m | — | -31.1% | -7.4% | −4.4% | −50% / unavailable |
| QNMEQuanome Technologies, Inc. | 13.4 m | — | -192.5% | -162.1% | +111.8% | −65% / unavailable |
| SLGBSmart Logistics Global Limited | 9.5 m | — | -13.4% | -2.9% | unavailable | −87% / unavailable |
| ELOGEastern International Ltd. | 9.2 m | — | -8.6% | -454.0% | −24.4% | −65% / unavailable |
| JYDJayud Global Logistics Limited | 9.0 m | — | -36.8% | -5.9% | +8.7% | −65% / −99% |
| SGLYSingularity Future Technology Ltd. | 2.6 m | — | -55.6% | -347.5% | −6.6% | −95% / −99% |
| FRGTFreight Technologies, Inc. | 1.6 m | — | -338.3% | -60.5% | −4.9% | −95% / −100% |
| GVHGlobavend Holdings Limited | 1.4 m | 0.6 | 9.0% | 2.9% | +42.5% | −76% / −100% |
| HUBGHub Group, Inc. | — | 0.1 | 6.3% | 2.8% | −6.1% | −30% / −29% |
1- and 3-year price returns: for QNME from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Quanome Technologies, Inc. (formerly Lakeside Holding Limited) currently operates mainly as a pharmaceutical distributor in China through Hupan Pharmaceutical, after disposing of its cross-border freight business. The company is moving into quantum technologies and AI compute infrastructure, activities still at an early stage with no revenue reported, so its profile is in transition. Revenue from continuing operations reached 5.85 mil USD in fiscal 2026 1.
SWOT
Strengths
- The company has an existing pharmaceutical distribution business with revenue and relationships with hospitals and distributors 1.
- The product portfolio includes different categories with varying profitability, which allows the sales mix to be adjusted 1.
- The company raised funds through its IPO and convertible debt, which supported its expansion 1.
Weaknesses
Opportunities
- If the AI and quantum initiatives secure contracts, they could diversify revenue beyond pharmaceutical distribution 1.
- Growing demand for innovative drugs and healthcare services could open new distribution segments 1.
- Partnerships with laboratories and research teams could speed up development in advanced technologies 1.
Threats
- Chinese regulation can change operations and the value of the shares, and the source warns these risks can be significant 1.
- Competitive pressure and centralized tendering can reduce margins in pharmaceutical distribution 1.
- Export control, sanctions and data protection requirements could limit AI services for certain customers 1.
Risks
- Regulatory risk in Chinahigh
Chinese authorities have influence over operations and access to capital markets, and changes in policy could affect the value of the shares 1.
- Dependence on suppliers and manufacturersmedium
The company relies on third parties for products and logistics, and supply interruptions could affect revenue 1.
- Customer concentrationmedium
A few large customers account for a significant share of sales, and losing them could affect results 1.
- Risk of new activitieshigh
The AI and quantum initiatives are at an early stage, their success is not assured, and they may consume significant resources 1.
- Listing riskmedium
US rules on audits of companies with operations in China could lead to trading restrictions if the required inspections cannot be carried out 1.
Investment thesis
What would need to be true (bull case)
- If the AI and quantum initiatives turn into contracts, the company could diversify beyond pharmaceutical distribution.
- Distribution revenue grew in fiscal 2026, showing the existing segment has traction in the Chinese market.
- The purchase of servers for AI compute indicates a concrete step toward a new business model, even though results remain uncertain.
What would break the thesis
- The net loss grew and operating expenses exceed revenue, which could put pressure on liquidity.
- The new activities have no contracted customers or revenue, and their outcome remains uncertain.
- Regulatory risks in China can affect operations and the value of the shares in ways that are hard to anticipate.
What to watch
- Signing of the first contracts for AI compute servicesnext 10-K
- Trend in net loss and operating expensesQ1 2027
- Whether quantum technology partnerships materialize2027
- Trend in customer concentration in pharmaceutical distributionnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company's core business is pharmaceutical distribution in China through its operating subsidiary Hupan Pharmaceutical, which sells infusion products, foods for special medical purposes and specialty pharmaceuticals to hospitals, distributors and other healthcare providers 1. It does not manufacture the products it distributes, but sources them from several manufacturers and uses logistics and warehousing providers for delivery. Sales are mainly made through agents, and revenue from continuing operations rose to 5.85 mil USD in fiscal 2026 1. In February 2026 the company transferred the operations of ABL Chicago, a cross-border freight business, to an unrelated third party, changing the shape of its portfolio 1. From August 2026 the company trades on Nasdaq Capital Market under its new name and the ticker QNME 1.
The company describes three areas of focus: pharmaceutical distribution, which generates revenue, quantum-related initiatives through its subsidiary Quantum Nexus, which have not yet generated revenue, and AI compute capacity and managed inference services through XDT Infrastructure I, LLC, which have no executed customer contracts yet 1. For the latter, the company has agreed to purchase 32 servers designed for high-performance AI computing 1. These initiatives are described as early-stage, so their effect on future results remains uncertain.
Segments
Pharmaceutical distribution (Hupan Pharmaceutical)
This is the only segment currently generating revenue. Products include infusion products, foods for special medical purposes and specialty drugs, and customers are hospitals and distributors, mainly reached through a network of agents 1. Public procurement and tenders influence sales volumes and margins 1.
Quantum technologies (Quantum Nexus)
This segment is in the evaluation and development stage and had not generated revenue as of the report date 1. The company is exploring applications in therapeutic discovery, healthcare, advanced materials, energy and cybersecurity, without a definitive partnership agreement yet 1.
Market context
The company operates in China's pharmaceutical distribution market, where competition is intense among national and regional distributors, wholesalers and specialized logistics providers 1. The market is heavily regulated, and pricing, centralized procurement and healthcare reforms can change margins 1. In fiscal 2026 the company generated revenue from 63 customers, four of which each accounted for more than 10% of revenue 1.
The markets for AI compute and quantum technologies are described in the source as still developing, with demand and competition not yet clear for a company that is entering them now 1. The company has no contracted customers in these areas and cannot yet estimate the size of the addressable market 1.
Trends
- Healthcare reforms in Chinamixed
Centralized procurement and price controls can reduce distributors' margins, but they can also open access to large contracts if the company qualifies 1.
- Ageing population and demand for innovative drugstailwind
The company identifies growing demand for complex and biologic treatments in the source as an opportunity to expand distribution 1.
- Price pressure and competitionheadwind
Price competition and participation in tenders can compress margins, and the source links this risk directly to the product mix 1.
- Interest in quantum and AI technologiesmixed
The focus on quantum computing and AI could attract investors and partners, but the company has no results in these areas yet 1.
Competitive position
In pharmaceutical distribution the company competes with national and regional distributors, wholesalers and specialized logistics providers, some of which have greater financial resources, wider networks and stronger supplier relationships 1. Competition turns on product availability, pricing, hospital access, tendering capability and service quality 1.
In AI compute and quantum technologies the source does not name specific competitors, but the company acknowledges it is building its team and infrastructure in a market that is still forming 1.
- National and regional pharmaceutical distributors in China
Direct competitors in pharmaceutical distribution, with wider networks and greater purchasing power, according to the source 1.
- Wholesalers and specialized distributors
Compete for tenders and for access to hospitals and other medical institutions, as the company describes it 1.
- Specialized pharmaceutical logistics providers
Compete on delivery, warehousing and management of the pharmaceutical supply chain 1.
- AI infrastructure and inference service providers
The source does not name specific competitors for the AI activity, but this is a market with many participants, where the company has no contracts yet 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report29 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report21 Oct 2026Material agreement · Financial statements and exhibits
- Current report09 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report05 Oct 2026Material agreement
- Current report01 Oct 2026Material agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
- Annual report25 Sept 2026
- Current report (amendment)25 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report23 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report21 Sept 2026Departure or appointment of officers
- Current report21 Sept 2026Material agreement
Sources
- [1] Form 10-K, fiscal year ended 2026-06-30 · SEC / Quanome Technologies, Inc. · 25 Sept 2026
- [2] Form 8-K, results release (exhibit 99.1) · SEC / Quanome Technologies, Inc. · 15 May 2025
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.